- Home
- UPXI vs XLO Comparison
UPXI vs XLO Comparison
Compare UPXI & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | XLO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 56.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UPXI | XLO |
|---|---|---|
| Price | $0.89 | $9.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.2M | 41.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,811,345.00 | ★ $43,766,000.00 |
| Revenue This Year | $118.99 | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.54 | $0.46 |
| 52 Week High | $9.12 | $9.89 |
Technical Indicators
Market Signals| Indicator | UPXI | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 55.21 |
| Support Level | $0.85 | $7.47 |
| Resistance Level | $0.93 | $9.89 |
| Average True Range (ATR) | 0.06 | 0.39 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 79.36 | 76.24 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.